Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial

OBJECTIVE: The risks of cardio-renal complications of diabetes increase with age. In the EMPA-REG OUTCOME® trial, empagliflozin reduced cardiovascular (CV) mortality by 38% in patients with type 2 diabetes (T2D) and CV disease. Here we compare outcomes with empagliflozin in older patients in EMPA-RE...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Age Ageing
Egile Nagusiak: Monteiro, Pedro, Bergenstal, Richard M, Toural, Elvira, Inzucchi, Silvio E, Zinman, Bernard, Hantel, Stefan, Kiš, Sanja Giljanovic, Kaspers, Stefan, George, Jyothis T, Fitchett, David
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2019
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7963112/
https://ncbi.nlm.nih.gov/pubmed/31579904
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ageing/afz096
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak